Vertex Pharmaceuticals, Inc.

Brian Ledford

Mark Willem Ledeboer

Tiansheng Wang

Francois Maltais

Luc J Farmer

Hongbo Deng

Randy Scott Bethiel

Wenxin Gu

Francesco Gerald Salituro

Upul Keerthi Bandarage

John P Duffy

Paul S Charifson

Huai Gao

Emanuele Perola

Joseph M Kennedy

Michael P Clark

Ioana Davies

David J Lauffer

Dylan H Jacobs

Robert J Davies

Michael John Boyd

Warren A Dorsch

Jian Jim Wang

Albert Charles Pierce

John J Court

Chao Lin

David Messersmith

Ronald Lee Grey, Jr

M Woods Wannamaker

Ursula A Germann

Yi Zhou

Min Jiang

Steven Jones

Ann Dak-Yee Kwong

Guy W Bemis

Pan Li

David D Deininger

Jinwang Xu

Suganthini S Nanthakumar

Randal Byrn

Elaine B Krueger

Michael D Mullican

Jingrong Cao

Cornelia Jutta Forster

Jon H Come

Leslie A Dakin

Timothy J Senter

Anne Fortier

Olivier Nicolas

Camil Sayegh

Nathan D Waal

Michael J Arnost

Mac Arthur Johnson, Jr

Marina S Penney

Russell R Hoover

Darin Takemoto

Michael Aaron Brodney

Jeremy Green

Dean P Stamos

Hayley Binch

Alex Aronov

Claudio F Sturino

Ales Medek

Yi Shi

Vincent P Galullo

Alexander Aronov

Kevin Gagnon

Peter Jamison Rose

Muna Shrestha

Craig Marhefka

Kira McGinty

Suganthi Nanthakumar

Janek Szychowski

Shi-Kai Tian

Lee Fader

Andrew Jayaraj

Greg Henkel

Martine Hamel

Francois Denis

Kan-Nian Hu

Faith Witkos

Andreas Peter Termin

Michael Robin Hale

Kevin Michael Cottrell

Arnaud Le Tiran

John E Cochran

Marion W Wannamaker

Yusheng Liao

Gabriel Martinez-Botella

Ioana Drutu

Emilie Porter Huck

Mark Cornebise

Mark N Namchuk

James Westcott

Jianglin Liang

Jun Feng

François Maltais

Jonathan Parsons

The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof for treating cellular proliferative disorders (e.g., cancer).

Pteridinone compounds and uses thereof

The disclosure provides at least one compound, deuterated derivative, or pharmaceutically acceptable salt chosen from compounds of formula (I), deuterated derivatives thereof, and pharmaceutically acceptable salts of any of the foregoing, compositions comprising the same, and methods of making and using the same, including use in treating APOL1 mediated kidney disease.

Inhibitors of APOL1 and methods of using same

The disclosure provides at least one entity chosen from compounds of Formula (I)

The disclosure provides at least one entity chosen from compounds of formula (I), solid state forms of the same, compositions comprising the same, and methods of using the same, including use in treating focal segmental glomerulosclerosis (FSGS) and/or non-diabetic kidney disease (NDKD).

The disclosure provides a compound of Formula (I), including deuterated derivatives, pharmaceutically acceptable salts, and solvates thereof, solid state forms of those compounds, compositions comprising those compounds and solid forms, and methods of using the same, including use in treating focal segmental glomerulosclerosis (FSGS) and/or non-diabetic kidney disease (NDKD). 

Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

Inhibitors of influenza viruses replication

Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

This invention provides methods of preparing 3-(pyrimidin-2-yl)-1H-pyrrolo[2,3-b]pyridines and 3-(pyrimidin-2-yl)-1H-pyrazolo[3,4-b]pyridines, or pharmaceutically acceptable salts thereof that are useful for inhibiting the replication of influenza viruses in a biological sample or patient, reducing the amount of influenza viruses in a biological sample or patient, and treating influenza in a patient.

Growing community of inventors

Norton, MA, United States of America

Brian Ledford